Texas Biomed News

Mymetics’ Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute | 09.30.2014

Epalinges, Switzerland, 29 September 2014 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial. The study will be led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program. | Read the full story

News 4 San Antonio Story Highlights Ebola Research at Texas Biomed | 09.22.2014

Lauren Lea with News 4 San Antonio reported in a story on September 19 how Texas Biomed has been working to detect, treat and discover a vaccine for the deadly Ebola virus. | Read the full story

Research Milestone in CCHF Virus Could Help Identify New Treatments | 09.18.2014

New research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne virus which causes a severe hemorrhagic disease in humans similar to that caused by Ebolavirus, has identified new cellular factors essential for CCHFV infection. This discovery has the potential to lead to novel targets for therapeutic interventions against the pathogen. | Read the full story

     

Biosafety Level 4 Laboratory

Learn More


Genomics Computing Resources

Learn More

Planning
Animal Research Saves lives
Support Texas Biomedical